Literature DB >> 6216285

Direct demonstration of the human suppressor inducer subset by anti-T cell antibodies.

C Morimoto, E L Reinherz, Y Borel, S F Schlossman.   

Abstract

Prior studies indicated that sera of patients with active juvenile rheumatoid arthritis (JRA) contain anti-T cell antibodies reactive with the T4+ inducer population. More important, depletion of this T cell subset with JRA anti-T cell antibodies (JRA+ T cells) and C abrogated T5/T8+ suppressor T cell function. In the present study, we utilized Ig-coated plate techniques and JRA anti-T cell antibodies to fractionate the T4+ population into T4+JRA+ and T4+JRA- subsets and characterize the individual T4+ inducer subset. It was shown that whereas only the T4+JRA- population responded maximally to the soluble antigens, TT and mumps, both T4+JRA+ and T4+JRA- subsets proliferated equally well to mitogens and alloantigens. Furthermore, B cell immunoglobulin production induced by T4+JRA- T cells was approximately twice that induced by the reciprocal T4+JRA+ subset. In contrast, the T4+JRA+ subset alone activated T8+ T cells to become suppressor effector cells. These results suggest that the T4+JRA+ subset is the inducer of suppressor subpopulation whereas the T4+JRA- subset functions maximally as the inducer of B cells. It is believed that the suppressor inducer population may have a central role in the immunoregulatory network in man.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6216285

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin.

Authors:  J D Bos; C Hagenaars; P K Das; S R Krieg; W J Voorn; M L Kapsenberg
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

2.  Phenotypic and functional characterization of T cells from patients with myasthenia gravis.

Authors:  F Mokhtarian; M Pino; W Ofosu-Appiah; D Grob
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

3.  Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis.

Authors:  R Gustafsson; T H Tötterman; L Klareskog; R Hällgren
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

4.  Schistosoma japonicum egg antigen-specific T cell lines in man. Induction of helper and suppressor T cell lines and clones in vitro in a patient with chronic schistosomiasis japonica.

Authors:  N Ohta; T Itagaki; M Minai; K Hirayama; Y Hosaka
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

5.  In vitro induction of HBsAg-specific CD8 CD11 human suppressor T cells.

Authors:  V Barnaba; G Ruberti; M Levrero; F Balsano
Journal:  Immunology       Date:  1987-11       Impact factor: 7.397

6.  Serum lymphocytotoxic activity in leprosy.

Authors:  F N Rasheed; M Locniskar; D J McCloskey; R S Hasan; T J Chiang; P Rose; R de Soldenhoff; H Festenstein; K P McAdam
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

7.  Activation of OKT4 suppressor cells in the autologous mixed lymphocyte reaction of patients with juvenile rheumatoid arthritis.

Authors:  K Oen; D Krzekotowska
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

8.  Neutralizing antibody prevents type D retrovirus viremia in Celebes black macaques.

Authors:  B J Wilson; S M Shiigi; J L Zeigler; L C Olson; A Malley; C F Howard
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

9.  Activation of antigen-specific suppressor T cells in the presence of cyclosporin requires interactions between T cells of inducer and suppressor lineage.

Authors:  N Mohagheghpour; C J Benike; G Kansas; C Bieber; E G Engleman
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

10.  Relationship between systemic lupus erythematosus T cell subsets, anti-T cell antibodies, and T cell functions.

Authors:  C Morimoto; E L Reinherz; J A Distaso; A D Steinberg; S F Schlossman
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.